Plus Therapeutics regains Nasdaq minimum bid price compliance after 1-for-25 reverse split

PLUS THERAPEUTICS, INC.

Nasdaq notified Plus Therapeutics on April 20, 2026 that bid price closed at or above $1.00 for 10 consecutive days through April 17.
Reverse stock split (1-for-25) was effective April 2, 2026 and enabled compliance with Listing Rule 5550(a)(2).
Nasdaq has closed the matter; PSTV common stock remains listed on The Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.